Fig. 7
Transportation of OXA@Fn across BBB. A Transportation ratio of OXA@Fn across in vitro BBB detected by fluorescence spectrophotometry. B, C The accumulation of OXA@Fn in GL261/TR cells after penetrating in-vitro BBB detected by flow cytometer and LSCM. D The effect of TfR1 antibody on transportation ratio of OXA@Fn across the in-vitro BBB detected by fluorescence spectrophotometry. E The effect of TfR1 antibody on the accumulation of OXA@Fn in GL261/TR cells after penetrating in-vitro BBB detected by flow cytometry. F The distribution of OXA@Fn in orthotopic TMZ-resistant glioma mice observed by in vivo bioluminescence imaging. G The distribution of OXA@Fn in main organs of orthotopic TMZ-resistant glioma mice observed by in vivo bioluminescence imaging. H Distribution of OXA@Fn in orthotopic TMZ-resistant glioma tissue observed by CLSM. CD31 staining: green (stands for blood vessel). Cy5 staining: red (stands for OXA@Fn). T: tumor tissue; N: normal tissue. I The content of Fe2+ in orthotopic TMZ-resistant glioma tissue. The OXA@Fn concentration was equivalent to 45 μg Fn/ml in cell experiment. The dose of OXA@Fn was equivalent to 3 mg OXA/kg in animal experiment. (n = 3, mean ± SD, **P < 0.01)